These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16732030)

  • 1. Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes.
    Tran MT; Navar MD; Davidson MB
    Diabetes Care; 2006 Jun; 29(6):1395-6. PubMed ID: 16732030
    [No Abstract]   [Full Text] [Related]  

  • 2. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
    Olansky L; Marchetti A; Lau H
    Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.
    Vergès B
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():15-8. PubMed ID: 18001314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients.
    Oz Gul O; Tuncel E; Yilmaz Y; Ulukaya E; Gul CB; Kiyici S; Oral AY; Guclu M; Ersoy C; Imamoglu S
    Metabolism; 2010 Jan; 59(1):64-9. PubMed ID: 19709689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose rosiglitazone in patients with type 2 diabetes mellitus requiring insulin therapy.
    Lopez CA; Kanna B
    Arch Intern Med; 2008 Mar; 168(5):548. PubMed ID: 18332304
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.
    Chogtu B; Singh NP; Chawla S; Gupta U
    Singapore Med J; 2009 Apr; 50(4):395-9. PubMed ID: 19421684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
    Chiquette E; Ramirez G; Defronzo R
    Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
    Sharma SK; Verma SH
    J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redefining the role of thiazolidinediones in the management of type 2 diabetes.
    Barnett AH
    Vasc Health Risk Manag; 2009; 5(1):141-51. PubMed ID: 19436665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
    Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
    Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.
    Derosa G
    Drugs; 2010 Oct; 70(15):1945-61. PubMed ID: 20883052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
    Tilden DP; Mariz S; O'Bryan-Tear G; Bottomley J; Diamantopoulos A
    Pharmacoeconomics; 2007; 25(1):39-54. PubMed ID: 17192117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations.
    Louisa M; Takeuchi M; Takeuchi M; Nafrialdi ; Setiabudy R
    Acta Med Indones; 2011 Jan; 43(1):39-52. PubMed ID: 21339545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glycemic control and cardiovascular benefit: what do we know today?].
    Egidi G; Popert U
    Dtsch Med Wochenschr; 2011 May; 136(19):1027; author reply 1027-8. PubMed ID: 21544796
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
    Boyle PJ; King AB; Olansky L; Marchetti A; Lau H; Magar R; Martin J
    Clin Ther; 2002 Mar; 24(3):378-96. PubMed ID: 11952022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ADOPT study. Glitazone controls diabetes progression].
    Einecke D
    MMW Fortschr Med; 2007 Jan; 149(1-2):10, 12, 14. PubMed ID: 17619358
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical practice effect of rosiglitazone discontinuation on glycemic control.
    Fanning EL; Weissman PN; Menditto LA
    Endocr Pract; 2009 Apr; 15(3):270-2. PubMed ID: 19364698
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.